The potential of biguanides, alpha-glucosidase inhibitors, DPP-4inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists as anti-obesity medications were highlighted in this study’s evaluation of many clinical trials that looked at antihyperglycemic treatments that have demonstrated weight loss effects. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.